Skip to main content
Retour
SRPT logo

Sarepta Therapeutics, Inc.

Qualité des données : 100%
Suracheté
SRPT
NASDAQ Healthcare Biotechnology
23,77 €
▲ 6,16 € (34,98%)
Cap. Boursière : 2,50B
Fourchette du Jour
19,67 € 23,85 €
Fourchette 52 Semaines
10,42 € 76,67 €
Volume
16 921 167
Moyenne 50J / 200J
18,99 € / 20,15 €
Clôture Précédente
17,61 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (631 pairs)

Métrique Action Médiane du Secteur
P/E -3,5 0,2
P/B 2,2 3,0
ROE % -53,5 3,5
Net Margin % -32,5 3,8
Rev Growth 5Y % 33,0 9,7
D/E 0,9 0,2

Objectif de Cours des Analystes

Hold
24,50 € +3.1%
Low: 16,00 € High: 32,00 €
P/E Prévisionnel
7,64
BPA Prévisionnel
3,11 €
Croissance BPA (est.)
+0,0%
CA Est.
1,71B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 1,35 €
0,95 € – 1,63 €
1,42B 5
FY2029 1,26 €
0,89 € – 1,51 €
1,44B 10
FY2028 1,03 €
-2,98 € – 4,60 €
1,41B 12

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-25 -1,20 € -3,58 € -199,0%
2025-11-03 0,01 € -0,13 € -1400,0%
2025-08-06 1,11 € 2,02 € +82,0%
2025-05-06 0,35 € -3,42 € -1077,1%
2025-02-26 1,38 € 1,50 € +8,7%
2024-11-06 -0,06 € 0,62 € +1139,7%
2024-08-07 0,01 € 0,07 € +1201,1%
2024-05-01 0,10 € 0,73 € +625,6%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Revenue grew 33,03% annually over 5 years — strong growth
Earnings declined -403,27% over the past year
Negative free cash flow of -307,45M
PEG of 0,01 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 17,45%
Capital efficient — spends only 4,64% of revenue on capex

Croissance

Revenue Growth (5Y)
33,03%
Revenue (1Y)15,58%
Earnings (1Y)-403,27%
FCF Growth (3Y)N/A

Qualité

Return on Equity
-53,47%
ROIC-22,63%
Net Margin-32,45%
Op. Margin-29,92%

Sécurité

Debt / Equity
0,91
Current Ratio2,32
Interest Coverage-67,60

Valorisation

P/E Ratio
-3,50
Forward P/E7,64
P/B Ratio2,19
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 15,58% Revenue Growth (3Y) 32,97%
Earnings Growth (1Y) -403,27% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 33,03% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2,20B Net Income (TTM) -713,41M
ROE -53,47% ROA -21,30%
Gross Margin 59,90% Operating Margin -29,92%
Net Margin -32,45% Free Cash Flow (TTM) -307,45M
ROIC -22,63% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,91 Current Ratio 2,32
Interest Coverage -67,60
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,50 Forward P/E 7,64
P/B Ratio 2,19 P/S Ratio 1,14
PEG Ratio 0,01 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 1,46 Fwd Earnings Yield 13,09%
FCF Yield -12,32%
Market Cap 2,50B Enterprise Value 2,73B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,20B 1,90B 1,24B 933,01M 701,89M
Net Income -713,41M 235,24M -535,98M -703,49M -418,78M
EPS (Diluted) -7,13 2,34 -5,80 -8,03 -5,15
Gross Profit 1,32B 1,58B 1,09B 793,02M 604,84M
Operating Income -657,77M 218,08M -267,82M -536,20M -459,71M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 3,35B 3,96B 3,26B 3,13B 3,15B
Total Liabilities 2,21B 2,44B 2,41B 2,74B 2,22B
Shareholders' Equity 1,14B 1,53B 859,34M 384,95M 928,01M
Total Debt 1,04B 1,34B 1,40B 1,62B 1,15B
Cash & Equivalents 801,28M 1,10B 428,43M 966,78M 2,12B
Current Assets 2,54B 3,07B 2,58B 2,56B 2,60B
Current Liabilities 1,10B 731,68M 653,66M 619,60M 452,73M

Scores de Stratégies

This stock passed the criteria for 0 strategies

Score = fit strength (0–100)
Rank = position among all matches

Activité Récente

Sorti Price/Sales Ratio Focus (Ken Fisher)
Mar 26, 2026
Entré Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026